ArticleGut2019
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
Article in Gut, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Approach to loss of response to advanced therapies in inflammatory bowel disease.World journal of gastroenterology · 2024Review
- Precision medicine and drug optimization in adult inflammatory bowel disease patients.Therapeutic advances in gastroenterology · 2023Review
- Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab.Frontline gastroenterology · 2022Article
- Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2021Article
- Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.Frontline gastroenterology · 2020Article
- Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.United European gastroenterology journal · 2019Article
- Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.BMC medicine · 2019Review
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29331941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.